Marsh Canada’s Life Sciences Practice provides risk management solutions based on in-depth knowledge of the risk exposures facing corporations in Canada—and around the world.

As a life sciences client of Marsh Canada, you are drawing from the full breadth of Marsh & McLennan Companies’ expertise and service solutions. Marsh has built its business model around practices dedicated to industry specialization. Marsh Canada’s Life Sciences Practice focuses on industry-specific needs allowing us to provide customized client solutions.

Your key business issues may include:

• Activism
• Brand Protection and Counterfeiting
• Business Continuity/Crisis Management
• Clinical Trial Risk Management
• Corporate Governance
• Cost of Risk Transfer
• Environmental Liability
• Intellectual Property
• Mergers and Acquisitions
• Sales Force Effectiveness
• Supply Chain Management
• War for Talent

And a host of other emerging issues given the rapidly changing global business environment.

Here are a few examples of how your Marsh Canada advisor can keep your business ahead of the risk curve.

Clinical Trial Risk Management

The growth in the number of clinical trials over the past five years has resulted in an increase in demand for appropriate risk management measures and clinical trial liability insurance. Marsh’s Life Sciences Practice tailors the appropriate risk management measures and clinical trials liability insurance for all parties involved in conducting clinical trials. Our clinical trial experts around the world can place locally admitted policies and are kept informed of changes in local legislation affecting clinical trial insurance requirements through the use of our Clinical Trials Matrix database.

Risk Transfer Solutions

Life Sciences companies are often subject to increasing premiums, and decreasing limits and options. As a leading broker for the life sciences industry, Marsh’s market presence helps ensure our clients receive cost-effective insurance programs tailored to our clients’ needs. Furthermore, our deep experience enables us to offer expert life sciences-specific benchmarking that can further reduce our clients’ cost of risk by helping them to make optimal insurance limit, retention, and pricing decisions.

Mergers and Acquisitions

Life sciences companies carry their own particular risks, and with each restructuring are presented with industry-specific challenges. Marsh’s Private Equity and M&A Services (PEMA) offers clients the full breadth of Marsh & McLennan Companies'  resources housed within all our operating units to help identify, quantify, and address the unique combination of risk issues associated with life sciences mergers and acquisitions transactions.